Management of cardiovascular disease in patients with psoriasis
Explore this paper's citation graph
Summary
The evidence associating psoriasis with CV disease, as well as the pharmacological and non-pharmacological treatment of CV risk factors including the CV effects of anti-psoriatic therapy and vice versa are described.
- Type
- article
- Published
- 2016-05-31
- Cited by
- 12
- References
- 113
- OpenAlex
- https://openalex.org/W27192114
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:12501641
Keywords
Humanities, Art, Political science
References
- Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis. An assessment of clinical significance when viewed as a risk factor for cardiovascular disease.
- Psoriasis is associated with lipid abnormalities at the onset of skin disease.
- Differential effects of anti-TNF-α and anti-IL-12/23 agents on human leukocyte-endothelial cell interactions.
- Risk of Cardiovascular Disorders in Psoriasis Patients
- Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis.
- The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity
- Psoriasis and risk of heart failure: a nationwide cohort study
- Effect of cyclosporine on blood pressure.
- Inflammation in Atherosclerosis: From Pathophysiology to Practice
- The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study
- Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study
- Prognosis following first‐time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study
- Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
- Adverse effects of biologics: a network meta-analysis and Cochrane overview.
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo‐controlled, phase III trials
- Cardiovascular outcomes and systemic anti‐inflammatory drugs in patients with severe psoriasis: 5‐year follow‐up of a Danish nationwide cohort
- Epicardial adipose tissue and coronary artery calcification in psoriasis patients
- ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
- The risk of mortality in patients with psoriasis: results from a population-based study.
- More than skin deep: atherosclerosis as a systemic manifestation of psoriasis
Cited by
- Treatment of Psoriasis Can Affect the Inflammation Burden
- Risk of Myocardial Infarction in Patients with Psoriasis and Psoriatic Arthritis: A Nationwide Cohort Study.
- Prediction of 30‐year cardiovascular disease risk in psoriatic population
- The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis
- Cardiometabolic disease in atopic dermatitis: the heart of the matter
- The association between cardiovascular disease and type 2 diabetes in adults with atopic dermatitis : a systematic review and meta-analysis Running head : Atopic dermatitis and cardiovascular disease
- Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis
- Cardiovascular Comorbidities in Psoriatic Disease
- Rosacea
- Crosstalk between cholesterol metabolism and psoriatic inflammation
- [Management of vascular risk in patients with psoriasis in primary care].
- Rosacea and Cardiovascular Comorbidities
- The role of biologic therapy for psoriasis in cardiovascular risk reduction.
Related papers
No related papers recorded.